MAXCYTE INC. - COMMON STOCK

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

15 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

12 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 May 2022 15:30:00 By Nasdaq GlobeNewswire

MaxCyte Reports First Quarter Financial Results

09 May 2022 15:05:03 By Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

03 May 2022 15:05:01 By Nasdaq GlobeNewswire

MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022

20 Apr 2022 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 Apr 2022 08:00:00 By Nasdaq GlobeNewswire

MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue

12 Apr 2022 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year Financial Results

22 Mar 2022 15:05:01 By Nasdaq GlobeNewswire

MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer

09 Mar 2022 15:15:00 By Nasdaq GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

24 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

14 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Feb 2022 16:00:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

01 Feb 2022 01:00:00 By Nasdaq GlobeNewswire

MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

24 Jan 2022 01:30:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

12 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter Financial Results

10 Nov 2021 15:00:00 By Nasdaq GlobeNewswire

MaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board

03 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Result of AGM

29 Oct 2021 11:40:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

28 Oct 2021 09:00:00 By Nasdaq GlobeNewswire